A target discovery agreement to identify disease-specific T-cell receptors (TCRs) in rheumatoid arthritis A data licensing ...

Adaptive Biotechnologies said on Monday it has signed two non-exclusive deals with Pfizer to support research in rheumatoid ...

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) has entered into two separate agreements with Pfizer Inc. (NYSE:PFE) that will see the companies collaborate on T-cell receptor (TCR) research to ...

Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment ...

As 2025 closes out, a pair of autoimmune biotechs have eked out separate deals with Big Pharma before year-end, each with a sizable potential payout down the line. | Seattle’s Adaptive Biotechnologies ...

A new review by Dr. Ruyuan Wang and an international team of researchers explores the complex interactions between the innate and adaptive immune systems, shedding light on regulatory mechanisms in ...

Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and ...

Detailed price information for Adaptive Biotechnologies Corp (ADPT-Q) from The Globe and Mail including charting and trades.

An evolutionary perspective on immune priming across plants and invertebrates highlights the roles of microbiomes and epigenetic regulation in shaping innate immune memory with promising applications ...